Optical Coherence Tomography-Guided Percutaneous Coronary Intervention With Low-Molecular-Weight Dextran - Effect on Renal Function

Circ J. 2020 May 25;84(6):917-925. doi: 10.1253/circj.CJ-20-0093. Epub 2020 Apr 29.

Abstract

Background: The excessive volume of contrast needed is a significant limitation of optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI). Low-molecular-weight dextran (LMWD) has been used for OCT image acquisition instead of contrast media. This study compared the effects of OCT-guided PCI using LMWD on renal function and clinical outcomes to those of intravascular ultrasound (IVUS)-guided PCI.

Methods and results: In all, 1,183 consecutive patients who underwent intracoronary imaging-guided PCI were enrolled in this single-center, retrospective, observational study. After propensity score matching, 133 pairs of patients were assigned to undergo either OCT-guided PCI using LMWD or IVUS-guided PCI. There was no significant change from baseline in the primary endpoint, serum creatinine concentrations, after the procedure in either group. There were no significant differences between the OCT and IVUS groups in the volume of contrast medium, the incidence of contrast-induced nephropathy (1.5% vs. 2.3%; P=0.65), and major adverse cardiovascular events (MACE) at 30 days (2.3% vs. 6.0%; P=0.12) and 12 months (2.3% vs. 3.0%; P=0.70) after the procedure. Kaplan-Meier analysis at the 12-month follow-up revealed no significant difference in the incidence of MACE between the 2 groups (P=0.75).

Conclusions: OCT-guided PCI using LMWD did not negatively affect renal function and achieved similar short- and long-term clinical outcomes to IVUS-guided PCI.

Keywords: Low-molecular-weight dextran; Optical coherence tomography; Percutaneous coronary intervention.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Biomarkers / blood
  • Coronary Artery Disease / complications
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / therapy*
  • Coronary Vessels / diagnostic imaging*
  • Creatinine / blood
  • Dextrans / administration & dosage*
  • Dextrans / adverse effects
  • Female
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Kidney / drug effects
  • Kidney / physiopathology
  • Kidney Diseases / complications*
  • Kidney Diseases / diagnosis
  • Kidney Diseases / physiopathology
  • Male
  • Middle Aged
  • Molecular Weight
  • Percutaneous Coronary Intervention* / adverse effects
  • Predictive Value of Tests
  • Retrospective Studies
  • Risk Factors
  • Tomography, Optical Coherence*
  • Treatment Outcome

Substances

  • Biomarkers
  • Dextrans
  • Creatinine